Inside the BeNeBio Trial: What Results of the First Randomized Study on Biologic Dose Reduction Actually Means

For years, the case for biologic dose reduction in psoriasis rested on expert opinion. In 2026, a global panel of 62 dermatologists across six continents agreed via the DR Delphi consensus that dose reduction is appropriate for patients whose disease has stayed controlled for six months or longer. That was a meaningful step. It still wasn't clinical proof.

But now, with the results of the BeNeBio trial, there is. Unlike other disease states, where remission guides a change in treatment, those on a biologic have historically remained on them indefinitely. This is often because no protocol for reassessment has existed after treatment starts. The BeNeBio study is the first randomized controlled trial to test dose reduction specifically in patients on IL-17 and IL-23 inhibitors, the newest and most expensive class of psoriasis biologics on the market. Results were recently published in The Lancet Regional Health – Europe and confirmed what dermatologists have been saying: a significant amount of patients on biologic drugs remain on a higher dosage longer than they actually need.

For the more than 8 million Americans with psoriasis, roughly a quarter of whom live with moderate to severe disease, BeNeBio shows us that clinically we must relook at how we treat psoriasis patients in biologics. Here I review what the BeNeBio trial tested and its results, and how a new approach to chronic dermatology care can operationalize these results to improve outcomes for members and reduce unnecessary specialty pharmacy costs.

What the BeNeBio Trial Tested

Researchers at 19 hospitals across the Netherlands and Belgium enrolled 244 adults with plaque psoriasis who had been on a standard dose of an IL-17 or IL-23 inhibitor for at least six months, with stable low disease activity (PASI ≤5 and DLQI ≤5). Patients were randomized 2:1, 164 to a dose-reduction protocol, 80 to continue usual care.

The dose-reduction protocol was stepwise, meaning biologic injection intervals were first extended to 67% of the standard dose, then, if disease activity stayed low, extended further to 50% of the standard dose. Patients were monitored every three months for 18 months, with dosing adjusted back up any time disease activity or quality of life slipped.

This showed us what a structured, disease-guided protocol looked like against usual care, in a randomized trial, with real-world real-life conditions.

What the Trial Found

The primary outcome of BeNeBio was whether dose reduction was non-inferior to usual care on the incidence of persistent flares (PASI >5 for three months or more) at 18 months. It was, with the difference between groups was 2.4%, well within the trial's 15% non-inferiority margin. No serious adverse events were tied to dose reduction.

The secondary outcome was how many patients actually sustained a lower dose. The numbers were high, with 76.2% of patients in the dose-reduction group achieving successful dose reduction at 12 months and 73.2% still successfully reduced at 18 months. This shows that it was not a one-time successful reduction, but sustainable over time. 

When it comes to a formulary, one detail worth knowing is success rates were successful, but not identical across drug classes. For patients on IL-23 inhibitors, 83.9% achieved successful dose reduction by 18 months and for patients on an IL-17 inhibitor, it was 61%.

Both are strong results but those on IL-23 inhibitors may have an even easier path to sustained dose reduction based on this trial.

Why This Matters More Than Current Information on Biologic Dose Reduction 

The DR Delphi consensus on biologic dose reduction told us what a group of fellow dermatologists agreed upon. A randomized controlled trial like BeNeBio tells us what actually happened to patients in a real-world setting. 

For a pharmacy or finance team at a health plan that's understandably skeptical of how clinical claims may be tied to cost savings, this distinction should matter. This isn't just a company’s internal data or experts’ opinion. It's peer-reviewed, published, independently funded research by the Netherlands Organization for Health Research and Development and the Belgian Health Care Knowledge Centre, not by a pharmaceutical company or biologic manufacturer. 

It's also the first trial to test this specifically on these newest, highest-cost biologics which are driving the fastest growth in dermatology specialty spend. IL-17 and IL-23 inhibitors are where a lot of the runaway spend is coming from today, and until now, there was little data around why.

What Health Plans Should Do Now

The BeNeBio trial answers the clinical question of whether dose reduction works and is safe for eligible patients on the newest biologics. While it doesn't answer the operational question around how to make sure patients get, or remain, on their right dose, it does support the reason why investing in a solution is worth it for health plans.

That’s where working with Zest Health comes in. Zest's clinicians apply structured, disease-guided reassessment to members already on biologic therapy, identifying who's a candidate for dose reduction and monitoring them through it, using the same disease-activity-guided approach validated in the BeNeBio trial. It’s operationalized for a health plan's population rather than one clinical trial site at a time and built to implement alongside your existing workflow, offered as an additional benefit for members with psoriasis.

The clinical evidence now opens health plans' eyes to the fact that looking at their members on these biologic drugs is a worthwhile exercise for both cost savings and ensuring clinical accuracy. The only question left is how fast your plan puts it into practice.